GPCR signaling

Peptide Biased Signaling Selective Pathway Activation

Tirzepatide's approval in 2022 sparked quieter excitement among structural biologists studying peptide biased signaling—how a single receptor activates different cellular pathways depending on which molecule binds to it. The University of Michigan and Eli Lilly teams mapped the mechanism with unusua